Mirum Pharmaceuticals, Inc. Other Noncash Income (Expense)
Mirum Pharmaceuticals, Inc. (MIRM) reported Other Noncash Income (Expense) of $577.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $299.00K, a 5.97% decline year-over-year.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was $278.00K, a 21.91% decline year-over-year.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was $382.00K, a 3.24% increase year-over-year.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $345.00K, a 23.33% decline year-over-year.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2025 was $1.40M, a 76.23% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2024 was $795.00K, a 24.57% decline from fiscal 2023.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2023 was $1.05M, a 69.95% decline from fiscal 2022.
- Mirum Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2022 was $3.51M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $299.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $577.00K 10-Q · filed 2026-08-05 | $959.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.30M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $278.00K 10-Q · filed 2026-05-06 | $660.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.00M derived: sum of 3 quarters · filed 2026-05-06 | $1.32M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $727.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.04M derived: sum of 3 quarters · filed 2026-08-05 | $1.40M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $345.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $663.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.02M 10-Q · filed 2025-11-04 | $1.39M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $318.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $674.00K 10-Q · filed 2026-08-05 | $1.04M derived: sum of 3 quarters · filed 2026-08-05 | $1.49M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $356.00K 10-Q · filed 2026-05-06 | $726.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.18M derived: sum of 3 quarters · filed 2026-05-06 | $1.43M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $820.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.08M derived: sum of 3 quarters · filed 2026-02-25 | $795.00K 10-K · filed 2026-02-25 | |
| 2024-09-30 | $450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $706.00K derived: sum of 2 quarters · filed 2025-11-04 | $425.00K 10-Q · filed 2025-11-04 | $454.00K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$25.00K 10-Q · filed 2025-08-06 | $4.00K derived: sum of 3 quarters · filed 2026-02-25 | $234.00K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | -$281.00K 10-Q · filed 2025-05-07 | -$518.00K 10-Q · filed 2024-05-08 | -$252.00K derived: sum of 2 quarters · filed 2026-02-25 | -$22.00K derived: sum of 3 quarters · filed 2026-02-25 | $620.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $259.00K derived: sum of 2 quarters · filed 2026-02-25 | $901.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.05M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $872.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.02M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $642.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $795.00K 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $153.00K 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $3.51M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |